Medicare AdvantageCoverageMedium impact
MA08.102g, Mogamulizumab-kpkc (Poteligeo®)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Jul 1, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage has updated the medical necessity criteria for Mogamulizumab-kpkc (Poteligeo®), a specialized oncology medication. This change affects the documentation and approval requirements for billing this drug to Medicare Advantage plans.
Action Required
By July 1, 2025: Billing team and oncology providers must review updated medical necessity criteria for Mogamulizumab-kpkc (Poteligeo®) billing to Medicare Advantage plans. Update prior authorization workflows and documentation requirements in billing system. Ensure providers are aware of new criteria to prevent claim denials.